Langues

molecular model for dual strategy

Pipeline

Neurolixis is building a drug discovery and development pipeline:
 

Development of early-stage clinical assets:

Neurolixis is developing clinical-stage drugs targeted at serious CNS diseases with unmet medical needs and sizeable market opportunity.

NLX-112, is a Phase II-ready drug intended for the treatment of L-DOPA-induced dyskinesia, a side-effect of Parkinson's disease treatment.

NLX-101, is a Phase I drug intended for the treatment of breathing difficulties in Rett's syndrome, a genetically-encoded orphan disorder.

 

Synthesis and development of Novel Chemical Entities (NCEs):

Neurolixis' is exploring validated, but underexploited, pharmacological targets for NCEs, including serotonin and glutamate receptors. New mechanisms of action will be favored, with a focus on "biased agonism".

 

All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.